| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SANTA CLARA, Calif.—Looking to expand its offerings in lab automation and robotics, Agilent Technologies announced it would acquire privately held Velocity11. Financial details were not disclosed, but the deal will see Agilent pick up about 150 employees as well as offices in Menlo Park, Calif., and Melbourn, Hertfordshire, U.K.
 
With a range of systems from standalone liquid handling stations to extensive, multi-armed robots, and associated control software, Velocity11's portfolio will deepen Agilent's repertoire of sample-prep solutions across the spectrum of drug discovery and development.
 
"Velocity11 is a market leader in lab automation with a solid reputation for innovative technology, quality products and superb customer service," said Nick Roelofs, vice president of Agilent's Life Science Systems and Solutions Unit. "Together, we can offer customers a comprehensive set of workflow solutions with increased levels of automation, which can help speed drug discovery and genetic research."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue